Patients are at the center of everything we do at GlycoMimetics. Through collaboration with our clinical partners, we are conducting clinical studies that explore the use of product candidates developed by our scientists in different oncology indications. Our central goal is to obtain the data required for review and approval by regulatory authorities, such as the U.S. Food and Drug Administration.
- Uproleselan (GMI-1271): This ongoing pivotal Phase 3 trial (NCT03616470) plans to enroll 380 patients ages 18 to 75 with relapsed/refractory acute myeloid leukemia who are considered to be medically eligible to receive intensive chemotherapy.
- Uproleselan (GMI-1271) is being evaluated by a consortium of the National Cancer Institute as a potential new treatment for newly diagnosed AML patients fit for chemotherapy. This is an ongoing effort with multiple sites across the U.S. participating.
- Rivipansel: In August 2019, Pfizer reported disappointing results from the Phase 3 RESET trial (NCT02187003) after it failed to meet the primary endpoint of the study. Following termination of Pfizer’s license agreement for rivipansel in April 2020 and the transfer of the full data set and IND, we committed to determine what, if any, next steps to take in vaso-occlusive sickle cell crisis.
To learn more about other clinical trials involving our product candidates, please visit ClinicalTrials.gov. ClinicalTrials.gov is a registry of publicly and privately supported clinical studies involving human participants conducted around the world. To find information on trials run by GlycoMimetics, our development partners, or by independent investigators, use the “Search for Studies” function and enter the product candidate’s name (e.g., uproleselan).